Crispr Therapeutics Ag
Crispr Therapeutics Ag is a Private limited company (Ltd.) registered in Switzerland under CHE494642722, and its current status with Zefix — Swiss Central Business Names Index is active. The company was incorporated on 31 October 2013 and lists its registered address as Zug, Switzerland. 8 shareholders are on record for Crispr Therapeutics Ag, and since every one of them is a company rather than an individual, this particular filing does not on its own establish an ultimate beneficial owner (UBO) — identifying one would mean tracing the ownership of each shareholding company in turn. This profile is sourced directly from Zefix — Swiss Central Business Names Index and was last updated on 25 September 2026.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
8
Shareholders of Crispr Therapeutics Ag
Eight shareholders are currently on record for Crispr Therapeutics Ag, reflecting the Aktienbuch (share register) maintained under Article 686 of the Swiss Code of Obligations rather than a public filing. The largest of these is UBS Group AG, holding 3.9% — the largest recorded stake — followed by Vanguard Group Inc at 3.5%; the remaining 6 shareholders shown hold smaller stakes. Because every shareholder shown is a company rather than an individual, the ownership chain continues above this level, and no beneficial owner can be established from this filing alone.
| Shareholder | Type | Holding | Source Document |
|---|---|---|---|
| UBS Group AG | 3.9% | Zefix — Swiss Central Business Names Index | |
| Vanguard Group Inc | 3.5% | Zefix — Swiss Central Business Names Index | |
| iShares Trust-iShares Russell 2000 ETF | 3.4% | Zefix — Swiss Central Business Names Index | |
| Geode Capital Management, LLC | 3.3% | Zefix — Swiss Central Business Names Index | |
| NEW PERSPECTIVE FUND | 3% | Zefix — Swiss Central Business Names Index | |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.6% | Zefix — Swiss Central Business Names Index | |
| GROWTH FUND OF AMERICA | 2.2% | Zefix — Swiss Central Business Names Index | |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.3% | Zefix — Swiss Central Business Names Index |
Officers
21
Directors and officers of Crispr Therapeutics Ag
The Ceo & Chairman of Crispr Therapeutics Ag currently on record is Samarth Kulkarni Ph.d.; 21 officers are currently on record for Crispr Therapeutics Ag, filed with Zefix — Swiss Central Business Names Index. Management authority at Crispr Therapeutics Ag sits with these individuals, not with shareholders, who are covered separately and hold ownership rather than control. The source filing doesn't specify representation authority — whether officers can act individually or must sign jointly to bind the company — so that detail isn't available here.
Group Structure
Group structure of Crispr Therapeutics Ag
Crispr Therapeutics Ag has no recorded parent company — it sits at the top of its own group structure, with 4 subsidiaries recorded beneath it across 3 jurisdictions. Each of these downward relationships is derived rather than filed: resolved by matching entities across the registry network, not stated directly in a single document.
- TRACR HEMATOLOGY LIMITED (United Kingdom)
- Crispr Therapeutics, Inc. (United States)
- CRISPR THERAPEUTICS LTD (United Kingdom)
- CTX Financing GmbH (Switzerland)
Data availability
Those 4 subsidiaries span Switzerland, United Kingdom, United States jurisdictions, though this list should not be read as complete — subsidiaries only become visible here where shareholder data has actually been filed with a register, so holdings in jurisdictions without that filing simply won't appear. One of the 4 go a level deeper still, with its own further subsidiaries recorded beneath it — additional ownership layers this view doesn't expand.
Crispr Therapeutics Ag
Switzerland
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
Who owns Crispr Therapeutics Ag?
Eight shareholders are currently on record for Crispr Therapeutics Ag, reflecting the Aktienbuch (share register) maintained under Article 686 of the Swiss Code of Obligations rather than a public filing. The largest of these is UBS Group AG, holding 3.9% — the largest recorded stake — followed by Vanguard Group Inc at 3.5%; the remaining 6 shareholders shown hold smaller stakes. Because every shareholder shown is a company rather than an individual, the ownership chain continues above this level, and no beneficial owner can be established from this filing alone.
Who is Crispr Therapeutics Ag's UBO (Ultimate Beneficial Owner)?
Every shareholder recorded for Crispr Therapeutics Ag is itself a company rather than a natural person, so no Ultimate Beneficial Owner (UBO) is identified at this level; establishing one would require tracing the ownership of each shareholding company in turn.
How many shareholders does Crispr Therapeutics Ag have on record?
8 shareholders are shown on record for Crispr Therapeutics Ag.
What is Crispr Therapeutics Ag's company registration number?
Crispr Therapeutics Ag's registration number is CHE494642722, filed with Zefix — Swiss Central Business Names Index in Switzerland. Its current status on the register is active.
Is Crispr Therapeutics Ag still an active company?
Crispr Therapeutics Ag's status on Zefix — Swiss Central Business Names Index is listed as active.
When was Crispr Therapeutics Ag incorporated?
Crispr Therapeutics Ag was incorporated on 31 October 2013, according to Zefix — Swiss Central Business Names Index.
What is Crispr Therapeutics Ag's registered address?
The registered address on file for Crispr Therapeutics Ag is Zug, Switzerland.
What legal structure is Crispr Therapeutics Ag registered as?
Crispr Therapeutics Ag is registered as a Private limited company (Ltd.) in Switzerland.
Who are the officers/directors of Crispr Therapeutics Ag?
The Ceo & Chairman of Crispr Therapeutics Ag currently on record is Samarth Kulkarni Ph.d.; 21 officers are currently on record for Crispr Therapeutics Ag, filed with Zefix — Swiss Central Business Names Index. Management authority at Crispr Therapeutics Ag sits with these individuals, not with shareholders, who are covered separately and hold ownership rather than control.
Does Crispr Therapeutics Ag have a parent company or subsidiaries?
Crispr Therapeutics Ag has no recorded parent company — it sits at the top of its own group structure, with 4 subsidiaries recorded beneath it across 3 jurisdictions. Those 4 subsidiaries span Switzerland, United Kingdom, United States jurisdictions, though this list should not be read as complete — subsidiaries only become visible here where shareholder data has actually been filed with a register, so holdings in jurisdictions without that filing simply won't appear. One of the 4 go a level deeper still, with its own further subsidiaries recorded beneath it — additional ownership layers this view doesn't expand.
Can Zavia monitor changes to Crispr Therapeutics Ag's ownership over time?
This profile reflects a point-in-time snapshot from Zefix — Swiss Central Business Names Index. Zavia's monitoring API can track changes to Crispr Therapeutics Ag's registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access Crispr Therapeutics Ag's data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including Switzerland, so records like Crispr Therapeutics Ag's registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Zefix — Swiss Central Business Names Index and was last synced on 25 September 2026.